Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. - Wikidata - awgldk - TriplyDB

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

http://www.wikidata.org/entity/Q34158407

about

Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ir Pregnant women's access to PMTCT and ART services in South Africa and implications for universal antiretroviral treatment.Risk factors of HIV-1 vertical transmission (VT) and the influence of antiretroviral therapy (ART) in pregnancy outcome.HIV-exposed infants: rethinking care for a lifelong condition.Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters.Mode of delivery and infant respiratory morbidity among infants born to HIV-1-infected women Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women.Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.Preterm birth and fetal growth restriction in HIV-infected Brazilian pregnant women.Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?Evidence of Subclinical mtDNA Alterations in HIV-Infected Pregnant Women Receiving Combination Antiretroviral Therapy Compared to HIV-Negative Pregnant Women.Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.Trends in birth weight and gestational age for infants born to HIV-infected, antiretroviral treatment-naive women in Malawi Preterm Birth and Low Birth Weight after In Utero Exposure to Antiretrovirals Initiated during Pregnancy in Yaoundé, Cameroon Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda.Combination antiretroviral use and preterm birth.Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025 Safety of protease inhibitors in HIV-infected pregnant women.Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial Trends in antiretroviral drug use during pregnancy among HIV-infected women on medicaid: 2000-2007.Postnatal cytomegalovirus exposure in infants of antiretroviral-treated and untreated HIV-infected mothers.Antiretroviral use during pregnancy for treatment or prophylaxis.HIV protease inhibitors in pregnancy : pharmacology and clinical use.Antiretroviral therapy and preterm birth in HIV-infected women.Adverse drug reactions associated with antiretroviral therapy during pregnancy.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Tolerance of the newborn to antiretroviral drug exposure in utero.Delivery After 40 Weeks of Gestation in Pregnant Women With Well-Controlled Human Immunodeficiency Virus.Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery.Darunavir for Use in Pregnant Women with HIV.Trends in live birth rates and adverse neonatal outcomes among HIV-positive women in Ontario, Canada, 2002-2009: a descriptive population-based study.Antiretrovirals in pregnancy: a note of caution.Increased risks of preterm birth and a low-birth-weight baby in Thai human immunodeficiency virus-positive pregnant women with periodontitis.

P2860

Q28066290-45595DF8-2C25-411F-AA0C-BF459B7A691D Q31043161-B1AF3EB0-1F97-472F-8C35-1268510D3A65 Q31043326-849F8171-7DA3-4308-A162-5C822814EE47 Q33859660-9C8FD38D-CD30-4855-AC4B-3007A5566BC7 Q33871174-43A14322-EFD8-40D9-AFB4-CBA407B7E9D0 Q34091313-AC062944-089E-4B21-BDF9-FC61BF3A315D Q34240876-8B772B52-BD8B-4A20-B09A-F627D9C46F4D Q34310482-C4C3A5C3-B88F-4B40-B1E6-2B2774FBE6B3 Q34408889-8ED06186-1F1E-4B16-ABD5-9FBA85B559A8 Q34988296-5C6E5BEA-C288-4D58-8C86-620FCA2EEC9A Q35075011-D0A20970-DAD1-47AD-AE5B-41C0FAEDC14A Q35129403-2DDC8038-B2A1-457D-B0F0-EDBFE9466A0A Q35551457-B50EDF8F-2701-4DC9-B87D-25A70C004D44 Q35617411-38F6C58F-5CAE-413D-81C6-BEF638725144 Q35691443-5D924AF3-8245-401E-8C9F-E6A1C5790F00 Q35738557-7AB3550B-382F-4002-9B09-72858324810B Q35738687-99815B6F-8FEB-498D-A9C1-7D847B931BA6 Q35897529-550FA747-30CF-4B01-8E83-FC38FC84910A Q35964999-F4E4C1E2-6B62-408B-A14D-C868DF9FA14D Q36072127-FD5809E8-D061-47D1-8AA2-DE2A669F7ABF Q36300046-A3D9C4E5-7E5B-4368-BAF0-585C27102BA5 Q36547343-3AF9EB91-FBA1-41ED-A114-7B3C64EC243F Q36851168-82FB4E99-7A66-4593-8292-6E9FAC59DC3C Q37215994-93AFC8E7-5E67-43D9-A8D9-899291841F93 Q37404428-E0352DC2-B920-4C4A-A2DA-9C822A74EF7B Q37498149-DCF58552-F126-4D7D-94E7-57CF2CB70133 Q37587959-C0333B59-C505-421B-9FDA-D54C027362F7 Q37644893-B56E2F59-B39C-459C-AC5C-29602F50B5B6 Q37870932-C56B6608-D6DA-4E27-A67A-9F2BC595FCF4 Q38081072-8FB2B203-5A6B-48ED-948A-3D2030770A8C Q38185748-02ED727F-B0F6-4DF7-9601-4F527A1768FD Q38267557-1421143D-9345-4237-A6BB-6EBE891EAFC0 Q38325427-CD7D8043-39AF-4BA9-B6E8-038463D9C45E Q38366365-70B80E8D-25BD-4AFE-BD47-DC121E145203 Q40087657-6B27BEBC-E633-464A-9344-2EB92303CDF9 Q41057213-4E58269C-1229-4CDE-B16F-C10BEBEA7D92 Q41922010-55A7F73D-61A9-494A-A34D-B468777440FF Q42223153-187FABB8-8A69-4F1D-97E7-C130A18420F2 Q42333841-3047752D-D6AD-4B46-9251-6EBC18B16658 Q45021366-C6AA2A77-8A90-437D-9883-99AF959C9DDD

P2860

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

http://www.wikidata.org/entity/Q34158407

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@ast

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@en

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@nl

type

label

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@ast

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@en

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@nl

prefLabel

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@ast

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@en

Prenatal protease inhibitor us ...... oviral drugs during pregnancy.

@nl

P1433

Q34158407-A4C33721-8FEA-41F3-AC11-4D7BEA368F45

P1476

Q34158407-ED259890-025E-4FD7-85C5-A4B2F41914A4

P2093

Q34158407-0B55C44F-9D71-4852-852B-401C4A4022FE

Q34158407-374AC2BF-FF3B-4690-A8FD-82EBED124A7A

Q34158407-639AEDA1-053E-4560-81C6-85663ABA95E4

Q34158407-B404895C-CB6A-46E9-893C-78B84AD7CB80

Q34158407-D8A49E86-9373-4040-9711-45A5AE09AAE1

Q34158407-EB25D14B-E44B-4A0C-B91F-A21DE3275034

Q34158407-EE7D1F45-D953-499A-AD3E-735A44A45257

P2860

Q34158407-017F8E89-8593-4EA5-9C40-9D16C5CC289E

Q34158407-2FD205A6-A861-4126-BBCC-3780DB405E7D

Q34158407-3DEBE4FE-C9A1-4734-ADC8-41740B2308A1

Q34158407-661823D8-DC85-47ED-BDDF-EBCA883C35E2

Q34158407-84A7A406-03D2-456E-8879-BC0B23E0F1AF

Q34158407-88F954A1-4C70-4E32-B17D-9B8AB283640B

Q34158407-9A1E8790-F04F-4555-A13B-03EE4CC2C8AE

Q34158407-ABEAD3C5-2F8F-47B8-BA83-67B731290274

Q34158407-B57B1E86-5AA3-4250-881E-2BC0B3F6E7B4

Q34158407-D67A9FEE-DE77-4133-B34B-808013F88760

P304

Q34158407-EAA301EA-ABF7-4B8B-AB52-CC7E8CEC78BA

P31

Q34158407-92A64F68-6480-4B56-AD7D-4FF650FB34D6

P356

Q34158407-6DA2B722-F74F-4E7A-B00D-8CA1599ACE1D

P407

Q34158407-11F3A6E7-BA75-42FF-9374-E8113AD2D20F

P433

Q34158407-6F246BF7-2E67-4601-8898-B616977F3520

P478

Q34158407-32DE7158-195D-472B-96F1-B4D8765CAFDE

P50

Q34158407-74DE9139-CDC3-4A32-94DE-308B7F765EA3

P577

Q34158407-7CDD0E39-A51E-4202-9AD6-DBA8200F43CA

P5875

Q34158407-F10A99A1-2EB9-4E19-84CD-39EFAE93D9DB

P698

Q34158407-7D7862FF-044A-4512-A19D-429F9B9DE60A

P921

Q34158407-917913DB-3762-4191-B857-E9E5A47A5413

Q34158407-EB48C785-F98B-4080-B7E6-2CAB038175AF

P932

Q34158407-D261177B-AAE3-4ADA-B8E3-42FCF60520F2

P356

P1433

The Journal of Infectious Diseases

P1476

Prenatal protease inhibitor us ...... roviral drugs during pregnancy

@en

P2093

Alice M Stek

http://www.w3.org/2001/XMLSchema#string

Arlene D Bardeguez

http://www.w3.org/2001/XMLSchema#string

David E Shapiro

http://www.w3.org/2001/XMLSchema#string

Elizabeth G Livingston

http://www.w3.org/2001/XMLSchema#string

Kunjal Patel

http://www.w3.org/2001/XMLSchema#string

P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group

http://www.w3.org/2001/XMLSchema#string

Ruth E Tuomala

http://www.w3.org/2001/XMLSchema#string

P2860

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

Management of human immunodeficiency virus infection in pregnancy

Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis.

Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.

Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women.

Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland.

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.

Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?

P304

1035-1044

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/651232

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41668477

http://www.w3.org/2001/XMLSchema#string

P698

20196654

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2946359

http://www.w3.org/2001/XMLSchema#string